Fig. 6.

BNIP3 is a tumor suppressor and is negatively correlated with FTO expression in breast cancer. a BNIP3 was significantly down-regulated various human cancer including breast cancer tumors comparing to the adjunct tissue. *P ≤ 0.05. b Overexpression of BNIP3 activated the cleavage of Caspase 3 and inhibited Bcl2 expression in MCF-7 cells. c-d Lower expression of BNIP3 was significantly associated with shorter overall survival in patients with breast cancer treated with taxane-anthracycline (c) and neuroblastoma (d). e Correlation analysis of the RNA levels of BNIP3 and FTO in breast tumor samples. f Protein expression levels of BNIP3 and FTO by immunohistochemistry assay in human FFPE breast cancer samples. g Correlation analysis of the protein levels of BNIP3 and FTO in breast tumor samples based on immunohistochemistry analysis. h-i BNIP3 expression level in 4T1-hypodermic breast tumor from mice treated with Rhein or FTO shRNA (h). The expression level was quantified as indicated (i). ***P ≤ 0.001